May Health, a Paris-based medical device startup focusing on helping women living with polycystic ovary syndrome (PCOS) restore ovulation and fertility, has secured $25 million series B funding to scale and advance its Ovarian Rebalancing™ therapy study. According to the company’s announcement on Monday, May 13, 2024, it secured the new capital through a funding May Health will use the new funding to support further developments for its Nobel Ovarian Rebalancing therapy for PCOS patients.
read more..